Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025

Rhea-AI Summary

Relay Therapeutics (Nasdaq: RLAY) will report third quarter 2025 financial results and corporate highlights after U.S. financial markets close on Thursday, November 6, 2025.

The company is a clinical-stage precision medicine firm combining computational and experimental technologies in drug discovery and is based in Cambridge, Mass.

News Market Reaction

-2.72%

1 alert

-2.72% News Effect

On the day this news was published, RLAY declined 2.72%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report third quarter 2025 financial results and corporate highlights after the U.S. financial markets close on Thursday, November 6, 2025.

About Relay Therapeutics

Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. Relay's Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The company’s lead clinical asset, RLY-2608, is the first pan-mutant selective PI3Kα inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. RLY-2608 is also being investigated in a group of genetic disease indications called PI3Kα-driven vascular malformations. Relay's pipeline also includes late-stage research programs for NRAS-driven solid tumors and Fabry disease. For more information, please visit www.relaytx.com or follow us on LinkedIn.

Contact:
Pete Rahmer
prahmer@relaytx.com

Media:
Dan Budwick
1AB
973-271-6085
dan@1abmedia.com

FAQ

When will Relay Therapeutics (RLAY) report third quarter 2025 results?

Relay Therapeutics will report third quarter 2025 results after U.S. financial markets close on November 6, 2025.

What will Relay Therapeutics announce on November 6, 2025 for RLAY?

The company will announce third quarter 2025 financial results and corporate highlights.

What is the Nasdaq ticker for Relay Therapeutics and where is it based?

The Nasdaq ticker is RLAY and the company is based in Cambridge, Mass..

Does the October 30, 2025 notice include Q3 2025 financial figures for RLAY?

No; the notice schedules the Q3 2025 report for November 6, 2025 and does not include financial figures.

What should investors expect in the November 6, 2025 Relay Therapeutics announcement (RLAY)?

Investors should expect financial results and corporate highlights for Q3 2025 to be released after U.S. markets close on that date.